Skip to content

Author

Elgene Lim

We have 2 of 13 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Rb-driven transcription limits its tumour-suppressive effects in breast cancer

The retinoblastoma protein (Rb) is a tumour suppressor best known for repressing E2F transcription factors and halting cell cycle progression1. In hormone receptor-positive (HR+) breast cancer, CDK4/6 inhibitors activate Rb by preventing its phosphorylation, forming a key component of current endocrine therapy regimens...

April C. Watt, Antonio Ahn, Catherine Blyth et al. · 2 citations
Open access Aug 2026

MDM2 inhibition restores p53 function to overcome dual endocrine and CDK4/6 inhibitor resistance in ER+ breast cancer

The case for clinical evaluation of MDM2 inhibition in this setting of urgent clinical need is supported, as NVP-CGM097 demonstrates single agent efficacy in dual-resistant ER+ breast cancer through G 1 arrest and senescence.

Leila Eshraghi, Fiona H. Zhou, Sarah Alexandrou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.